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Abstract
The cyclin dependent kinase (CDK) inhibitors p15, p16, p21 and p27 are frequently deleted,
silenced or downregulated in many malignancies. Inactivation of CDK inhibitors predisposes mice
to tumor development demonstrating that these genes can act as tumor suppressors. Here we
describe high-throughput murine leukemia virus (MuLV) insertional mutagenesis screens in mice
deficient for one or a combination of two CDK inhibitors. We retrieved 9117 retroviral insertions
from 476 lymphomas and find hundreds of loci that are mutated significantly more frequently than
expected by chance. Many of these are skewed toward a specific genetic context of predisposing
germline and somatic mutations. We also find associations between these loci and gender, age of
tumor onset and with lymphocyte lineage (B or T cell). Comparison of retroviral insertion sites
with SNPs associated with chronic lymphocytic leukemia (CLL) reveals significant overlap
between these datasets. Together these data highlight the importance of genetic context within
large-scale mutation detection studies and demonstrate a novel use for insertional mutagenesis
data in prioritization of disease associated genes resulting from genome-wide association studies.
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Introduction
Recent mutation profiling of human tumors has implicated hundreds of genes in the
pathogenesis of cancer; however, the vast majority of these genes are only rarely mutated,
making it difficult to determine which events are causal “driver” mutations and which are
incidental “passenger” mutations (reviewed in (1)). Retroviral insertional mutagenesis
screens performed in mouse models of cancer are a useful complement to studies of human
tumors, because they provide an independent validation of oncogenic mutations in another
organism (2). In these screens, slow transforming retroviruses are used to induce mutations
within somatic tissues (3). Over the lifetime of the mouse these mutations accumulate,
eventually promoting clonal expansion of cells bearing multiple oncogenic mutations. Since
viral insertion sites can be easily identified by PCR, a high proportion of the mutations in
each tumor can be identified with relatively little effort. This coverage allows for
identification of genetic interactions between mutations at rates that are not yet possible
from the study of human tumors. Furthermore, the use of mice allows the identification of
cancer genes that collaborate with specific cancer-predisposing lesions that have been
introduced into the germline.
Cyclin/cyclin dependent kinase (CDK) complexes promote the progression of cells through
the cell cycle. Deregulation of CDKs is implicated in the progression of a variety of cancers
including hematological malignancies (reviewed in (4)). Based on structural and functional
characteristics, two families of CDK inhibitors can be distinguished: the Ink4 family
(p16Ink4a, p15Ink4b, p18Ink4c and p19Ink4d) and the Cip/Kip family (p21Cip1/Waf1/Sdi1,
p27Kip1 and p57Kip2)(reviewed in (5)). The Ink4 proteins specifically inhibit cyclinD-cdk4-6
complexes and expression of Ink4 genes results in a G1-phase-cell-cycle arrest. p15Ink4b and
p16Ink4b as well as p19Arf (which shares part of its coding sequence with p16Ink4a in a
different reading frame), are located in the same chromosomal region that is frequently
deleted in human cancer (6). Germline knockout studies have shown that loss of p15 and
p16 predisposes mice for tumor development, confirming their role as tumor suppressor
genes (7-10).
The Cip/Kip proteins have a broader spectrum of substrates, binding to cyclin D-, cyclin E-
and cyclin A-dependent kinase complexes. The p27 and p21 genes are rarely subject to
inactivating mutations in human cancer, but can be inactivated by other mechanisms
(reviewed by (5)). Mouse studies have clearly indicated that p27 is a tumor suppressor gene
(11, 12). Germline disruption of p21 may have both anti- and pro-oncogenic effects
depending on the genetic context (13-15).
We performed retroviral insertional mutagenesis in mice deficient for one or more Ink4 and/
or Cip/Kip family members in order to identify genes that collaborate with absence of these
CDK inhibitors in cancer. Analyzing tumors from 476 mice we identified 9117 insertions,
finding hundreds of common insertion sites (CISs) targeting known cancer genes as well as
novel candidate cancer genes. Many of these CISs are specifically mutated in mice lacking
one or more CDK inhibitors. Furthermore, we find CISs correlating with the cell type of
origin and latency of the tumor, as well as co-occurring or mutually exclusive combinations
of mutations. We also found a significant correlation between the location of SNPs
associated with familial CLL and CISs, indicating that insertional mutagenesis data may be
of use in identifying disease-associated genes.
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Materials and methods
Mice strains and induction of tumors by MuLV infection
Some tumors were described in prior studies (16-18). p15Ink4b-deficient mice are described
in (7). Newborn pups were injected i.p. with supernatant of MuLV-producing NIH3T3s.
Animals were monitored for the development of tumors, moribund mice were sacrificed and
tumors were isolated.
Cloning of insertion sites
Ligation-mediated splinkerette PCRs were performed as described (19). Two ligations were
performed for each tumor, using DNA digested with Sau3AI and Tsp509I. PCR products
were shotgun subcloned and 96 colonies per PCR reaction were picked and sequenced on a
capillary sequencer. Insertions will be available online at the Mutapedia1 and RTCGD
databases2.
Informatics
Sequences were mapped onto NCBI mouse build 37 using exonerate (20). Sequences from a
single mouse with an identical insertion site were merged. CISs were identified and their
significance estimated using the kernel convolution method described in (21). CIS labels
were manually annotated based on viral position and literature analysis. P-values for
associations between CISs and genotype, gender, age, FACS markers and co-occurring
mutations were calculated using Fisher's exact test. Identification of genes and loci with
more than one insertion per tumor at a higher frequency than expected by chance is as
described (22), however for random permutations inserts were shuffled between mice of the
same genotype rather than between all genotypes together to minimize false positives.
Results
Identification of MuLV insertion sites and common insertion sites in CDK-deficient mice
To identify genes that collaborate in tumorigenesis with deficiency for p15, p16/p19Arf, p21
and p27, we performed retroviral insertional mutagenesis in mice deficient for one or a
combination of these genes. p27−/− mice developed tumors significantly faster than wild-
type mice. p21 deficiency had no effect on tumor latency even when combined with loss of
p27 (17) (Supplementary Table S1). Mice deficient for both p19Arf and p16 also show
accelerated tumor formation upon MuLV infection (18), whereas p15 deficiency
significantly decelerates tumor formation compared to wild-type controls (Logrank test, p-
value < 0.04).
To identify the genes that are mutated by retroviral insertions we amplified the flanking
sequences of the insertions using a ligation-mediated PCR protocol followed by shotgun
subcloning and sequencing as described previously (19, 22). Previously 931 insertion sites
were cloned from a subset of 189 of these tumors (16, 18): an average of 6.6 inserts per
tumor. In the current study, using an improved PCR protocol in combination with shotgun
subcloning, we identified 9117 independent insertions from 476 tumors (~19 insertions/
tumor) (Supplementary Table S2).
Loci that are mutated at a frequency higher than expected by random chance may contain
cancer genes. To identify these common insertion sites (CISs), we created a density
distribution of insertions over the genome using smoothed Gaussian kernels, and estimated
1http://mutapedia.nki.nl
2http://rtcgd.ncifcrf.gov
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significance of each peak by comparison to 10,000 permutations of insertions randomly
distributed over the genome (21). Using a kernel width of 30 kb, we identified CISs for the
separate tumor panels (Figure 1A). We identified many CISs near known or candidate
cancer genes, and their prevalence varies between genotypes. For example, some CISs are
uniquely found in single knockouts but not in the compound knockouts and vice versa
(Supplementary Table S3).
Genotype- and gender-specificities of CISs
We next asked which CISs are more frequently mutated in one genotype versus another. For
this and subsequent analyses we pooled our insertions with approximately 11,000 insertions
from 510 MuLV-induced wild-type, p19Arf- and p53-deficient tumors (22) to extend the
number of different genotypes that can be compared, as well as to improve the power of any
statistical tests that use all tumors. After identifying CISs (596 using a 30kb kernel, and 300
using a 300kb kernel, Figure 1A and 1B, Supplementary Table S4), we determined which
CISs are mutated significantly more frequently in one genotype versus the other genotypes
by pairwise Fisher's exact tests (Supplementary Table S5 lists all significant associations).
To visualize multiple pairwise comparisons per CIS we represented the associations of each
CIS as a heat map.
The top 12 CISs are mutated significantly more frequently in some genotypes than others
(Supplementary Figure S1). Myc and Mycn are structurally and functionally equivalent in
many respects (23). Consistently, both genes show a significant bias towards p27-deficient
tumors (Figure 2A) however, Myc but not Mycn is selected against in p15−/− and
p16−/− p19Arf−/− tumors. The genotype-specificities of the Cyclin D family members Ccnd3
and Ccnd1 also differ. Ccnd3 is less frequently mutated in p16−/− p19Arf−/− mice compared
to other genotypes including p19Arf−/− mice, whereas the opposite is found for Ccnd1
(Figure 2B), suggesting that activation of Ccnd1 but not Ccnd3 provides a selective
advantage in the absence of p16. A similar difference in genotype-specificities is found for
mutations near the miRNA cistron encoding mmu-mir-106-363 and its paralog mmu-
mir-17-92 (Figure 2B). This differential specificity of paralogs is a recurrent phenomenon;
CISs for Runx1 and Runx3, Pim1 and Pim2 and Rasgrp1 and Rasgrp2 are also selected for
in different genetic backgrounds suggesting distinct roles in tumorigenesis despite their
homology (Supplementary Figure S2).
Some CISs are surprisingly specific for compound genotypes but not single knockouts
(Zfp217 and Fli1/Ets1 are selected for more frequently in p15−/− p21−/− mice than p15−/− or
p21−/− single knockouts) or for heterozygotes but not homozygotes (CISs near Sox4 or
Cebpb/A530013C23Rik/Ptpn1 are more frequently mutated in p16+/− p19Arf+/− compared to
wild types or p16−/− p19Arf−/−) (Supplementary Figure S3). Heat maps for full sets of
genotype associations are available online (http://mutapedia.nki.nl).
In a similar fashion, we examined the association of all CISs with gender (Table 1). The
Trim25/Dgke CIS is selectively mutated in female mice compared to males. Trim25 is an
estrogen-responsive gene that promotes breast cancer growth by targeting the anti-
proliferative 14-3-3s for proteolysis (24). Mutation of two Irf family members, Irf4 and Irf2,
is selected for in female mice (at the 30 kb and 300 kb scales respectively (Table 1 and data
not shown)). These oncogenes are thought to act via inhibition of transcription of the tumor
suppressor Irf1. Female mice lacking Dev6 (a negative regulator of Irf4 (25)) develop a
systemic autoimmune disorder more frequently and at an earlier age than males. This
lymphadenopathy is similar to human systemic lupus erythematosus, which also occurs
more frequently in females than males (26).
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Correlating CIS genes with tumor phenotype
Since average tumor latency differs between genotypes (Supplementary Table S1), we
reasoned that the insertion profile of tumors would also significantly influence tumor
latency. To separate the effects of genotype on latency from the effect of insertions, we
normalized tumor latencies between all genotypes by assigning each mouse a percentile
lifespan within its cohort. Using these values two pooled cohorts were assembled, one
containing the short latency mice from each genotype (< 50th percentile) and a cohort that
contained the long latency mice from each genotype (> 50th percentile). Next, we examined
what CISs were significantly more frequently mutated in the ‘short-latency’ cohort versus
the ‘long-latency’ cohort and vice versa (Table 2).
Gfi1, Mycn and Tbxa2r are most preferentially mutated in the ‘short-latency’ cohort, as well
as the CIS upstream of Myc. In contrast, CISs found downstream of Myc that may also
affect Pvt1 expression (27) are more frequently mutated in mice with a longer lifespan,
suggesting distinct effects in tumorigenesis. Notch1, Lfng and Ikzf1 (Ikaros) have been
found to collaborate in tumorigenesis (28) and are mutated in the ‘long-latency’ cohort
indicating that mutation of these genes is either not as potent as others, or is only tolerated or
selected for after other predisposing mutations have taken place.
We analyzed many of the tumors from the p19Arf−/−, p53−/− and wild-type screen for T or B
cell content using T and B cell-specific markers (CD3 and B220, respectively) for FACS
analysis (22). We separated splenic and thymic tumors and ranked them on T or B cell
content to investigate if CISs were preferentially mutated in tumors with high or low
percentages of T or B cells. Both Flt3 and Kdr (Vegfr2), known oncogenes in human
hematopoietic malignancies, are selectively mutated in splenic tumors with a high content of
B220-positive cells, suggesting that these genes might contribute to B cell lymphomagenesis
(29, 30) (Supplementary Table S6). Conversely, mutations near mmu-mir-106-363 were
found in spleen tumors with high levels of CD3-positive cells and low levels of B220-
positive cells, indicating that this gene may be involved in the development of T cell tumors.
Genetic interactions between CISs
We and others have previously observed strong selection for or against co-mutation of
certain CISs (22, 31). To identify co-occurring and mutually exclusive mutations we
performed two analyses: First, we pooled the insertions from the current study with our
previous study of p53−/−, p19Arf−/− and wild-type tumors in order to maximize the statistical
power of our tests for co-mutation. However, we also postulated that pooling unlike
genotypes might create false interactions between CISs that are enriched in one genotype
versus another. To correct for this effect in CIS interactions, we also calculated interactions
for all the genotypes separately. The increased number of tumors over our previous study
gives higher statistical power to many of the associations found previously (22) and
identifies hundreds of new interactions many of which are skewed towards particular
genotypes (Supplementary Table S7A and S7B).
Many of the interactions that were significant in the pooled data showed a similar trend in
one or more genotypes analyzed separately. For example, using a 300 kb window we find
significant co-occurrence of inserts near Myb/Ahi1 and Rras2 and significant mutual
exclusivity of Myc/Pvt1 and Mycn in multiple genotypes (Figure 3A). Some recurrent
interactions appear to be remarkably genotype-specific for mice lacking both alleles of
p19Arf (p19Arf−/− and p16−/− p19Arf−/−) (Figure 3B) or for p16−/− p19Arf−/− and p53−/− mice
(Figure 3C). It is important to note that many of the mutually exclusive interactions are not
observed in individual panels (FliI and the mmu-mir-106a cluster, Rras2 and Map3K8)
(Figure 3D) suggesting that bias of these CISs towards different genotypes is at least
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partially responsible for the rarity of these co-mutations. Thus whilst pooling panels lends
statistical power to identification of co-occurring and mutually exclusive mutations, it is
important to simultaneously stratify tumors into separate subpanels to observe whether these
interactions are an indirect byproduct of genotype-specificity.
Using a 30 kb kernel width, many associations appear to be recurrent for different CISs of
the same locus. For instance, the 30 kb CIS of Gata1 significantly co-occurs with Runx1 30
kb CISs #1, #5 and #6 (Supplementary Table S7A). Gata1 mutations removing the N-
terminus of the protein are frequently detected in Down syndrome patients with transient
myeloproliferative disorder and acute megakaryoblastic leukemia (32) and even some
patients with no apparent hematopoietic disorders. This suggests that selection for Gata1
mutations is a direct consequence of trisomy 21. Human chromosome 21 encodes more than
250 protein-coding genes. Runx1 is one of 7 loci associated with Gata1 in our screens, but it
is the only one located within regions of the mouse genome sharing a common origin with
human chromosome 21. Runx1 and Gata1 are transcription factors that bind each other and
cooperate to activate genes involved in hematopoietic differentiation (33). The role of
Runx1 dosage in trisomy 21-induced Gata1 mutation remains controversial (34), however,
concomitant mutation of these loci in mouse lymphoma supports the hypothesis that Runx1
is at least one of the genes on chromosome 21 promoting selection for Down syndrome-
associated Gata1 mutation.
Another novel interaction with precedent in the literature is the co-occurrence of mutations
in Lck and the Stat5a/Stat5b/Stat3 locus. The Lck kinase is required for phosphorylating the
Stat5a and Stat5b transcription factors in response to T cell receptor signaling and enhances
DNA binding of Stat3, Stat5a and Stat5b (35, 36), supporting a scenario in which Lck and
Stats collaborate in tumorigenesis (Supplementary Table S7A).
Identification of tumor suppressor candidate genes
MuLV insertions can inactivate tumor suppressor genes through disruption of transcripts. It
is difficult to distinguish which insertions are likely to be activating or inactivating based
solely on location and orientation of the insertions. We previously hypothesized that the
presence of more than one insertion within the transcribed region of a gene in cancer
suggests selection for loss of both copies (i.e. the gene is a tumor suppressor). However, the
most frequently mutated oncogenes may also have more than one insertion within them
through chance (either in the same cell or in different subclones). We have previously
distinguished between these events by looking for genes that have more than one insertion
within the transcribed region within the same tumor more frequently than expected by
chance (22).
Using similar methodology in the current analysis, pooling insertions from all panels, we
find 82 genes with more than one insert per tumor (Supplementary Table S8). 44 genes have
more than one insertion per tumor at frequencies higher than expected by chance, including
some new candidate tumor suppressor genes like Rere (p-value 0.007) and Anks1 (or Odin,
p-value 0.01). Rere was found to be located in the minimally defined loss of heterozygosity
region at 1p36.2-p36.1 in a neuroblastoma cell line (37). Embryonic fibroblasts from Anks1-
deficient mice exhibited a hyperproliferative phenotype compared with wild-type
fibroblasts, consistent with a role for Anks1/Odin as a negative regulator of growth factor
receptor signaling (38, 39).
For some genes there appears to be selection against a second insertion within the gene in
the same tumor. Insertions within the Mycn transcript are suspected to be stabilizing the
transcript (40). Of the 78 inserts within this gene, only one tumor carries more than one
insertion, whereas in randomized data on average 3.9 tumors have more than one insert in
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this gene. Similarly, significant selection against more than one intragenic insertion is also
observed within Ahi1 and Pvt1. The simplest explanation may be that mutation of the first
allele of each of these genes is sufficient to remove any selection for a second mutation.
A number of verified tumor suppressor loci that would be anticipated to be downregulated
during tumor development (Ikzf1, p53, Nf1), have insertions outside the transcribed region.
Thus, rather than limiting our analysis to gene boundaries we also looked for CIS windows
with more than one insertion per tumor at frequencies higher than expected by chance
(Supplementary Table S9). The most significant CIS in this analysis was Cbfa2t3 (Core-
binding factor, runt domain, alpha subunit 2, translocated to 3), which aside from its
involvement in an AML translocation (41) is suspected of being a tumor suppressor in
human breast cancer (42). Smyd4, the second most significant CIS in this analysis is
implicated to be a tumor suppressor gene in breast cancer development since its expression
is lost in a subset of human breast tumors and suppression of Smyd4 expression stimulates
proliferation of mammary cells in vitro (43). Retroviral insertions may inactivate these genes
by mutation of their promoters and enhancers or methylation induced by proviral sequences
might silence these genes (44).
Cross-species comparison of MuLV insertional mutagenesis data and SNP loci from
familial Chronic Lymphocytic Leukemia (CLL)
A recent genome-wide association study of 511 CLL cases (155 with a family history of the
disease) using 346,000 single nucleotide polymorphism (SNP) arrays identified 49 SNPs
distributed over 35 loci that were significantly associated with the disease. 17 SNPs were
chosen for further validation, and 7 were found to significantly associate with disease in two
independent validation cohorts (45). Observing that one of the validated loci is orthologous
to one of our CISs (IRF4), we tested whether the entire set of 49SNPs/35 loci from the first
phase of screening significantly overlaps with our insertions.
Each of the 49 SNPs was mapped to its orthologous position in the mouse genome using the
Ensembl Compara database. To avoid redundancy, loci bearing more than one SNP were
grouped into a single coordinate representing the average position of all SNPs, yielding 35
loci in total. Using windows ranging from 10 kb up to 300 kb surrounding each orthologous
position we observed enrichment of our insertions within these windows (Table 3). To
estimate the significance of this overlap, we compared the number of insertions within
windows surrounding the orthologous loci of SNPs to 1000 permutations of windows
surrounding random loci (random gene start sites). For all window sizes, orthologous loci of
SNPs had more insertions than expected for random loci. The degree and significance of this
enrichment varied between a maximum of 2.61 fold (70 kb window p-value 0.016) and a
minimum of 1.56 fold (300 kb window p-value 0.066). In addition to finding retroviral
inserts within 150kb of five of the six loci that were previously validated in independent
CLL patient cohorts (ACOXL/BCL2L11, IRF4, CR17890/GRAMD1B, AK097902/
BC029061, PRKD2/FKRP/SLC1A5)(45), we also find inserts near a number of SNPs not
significantly associated with disease in the validation cohorts (which might justify further
investigation of these SNPs in larger validation cohorts) and some SNPs not chosen for
rescreening in the validation cohorts (suggesting these may warrant screening in a validation
cohort) (Supplementary Table S10).
Discussion
We isolated 9117 retroviral insertions from a cohort of 478 MuLV-induced tumors derived
from mice deficient for one or a combination of two CDK inhibitors to identify genes
contributing to tumorigenesis in these backgrounds. Combining this dataset with insertions
from a previous screen, we identified 596 CISs at a kernel width of 30kb, more than 250 of
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which had not been found in our previous screen. The 596 CISs are enriched for loci in the
vicinity of paralogs of human cancer genes ((22), Mattison et al., submitted). By comparison
of 13 genotypes we have illustrated that given sufficient statistical power, the majority of
oncogenes and tumor suppressors mutated in these screens are greatly influenced by
deficiency for alleles of one or more CDK inhibitors. We also observe that whilst some
combinations of retroviral mutations are recurrent in many genotypes, others are clearly
dependent on a specific genetic background.
MuLVs can give rise to lymphoid, myeloid and erythroid tumors with the relative frequency
of these being influenced by both host genotype and virus substrain. Ecotropic MuLVs
infect cells through the mCAT-1/Slc7a1 receptor (46), which is expressed in a variety of
hematopoietic lineages, making the cell type of origin of these tumors unclear. Germline
mutation of Cdk inhibitors may shift the balance between cell populations in the lymphoid
compartment and thus affect the cellular composition of the tumors (17). Thus whilst the
prevalence of CISs in each genotype may stem from cell-intrinsic effects of tumor
suppressor loss within the tumor-initiating cells, they may also be influenced by the relative
size of different hematopoietic populations within each genotype.
Resources for validation in genome-wide association studies are currently limiting.
Integration of independently derived datasets such as mouse retroviral insertions and human
genome-wide association studies can help in prioritizing validation of loci, particularly those
with no prior suggested role in cancer. Such comparisons are also useful because in many
cases the relationship of SNPs to disease genes is unclear. Whilst the position of our
retroviral insertions in mice frequently implicates the gene that is nearest to the SNPs in
humans (as is the case for SNPs and inserts near Ccnd2 and Runx3) this is not always the
case (Supplementary Table S10). For example, one SNP on chromosome 21 is nearest to
Cryaa, however six insertions in the orthologous region on chromosome 17 in mice appear
most likely to deregulate Snf1LK, an AMP activated kinase implicated in cell cycle
regulation which is found to be overexpressed in murine lymphoma (47, 48). Snf1LK is a
regulator of CREB1, a transcription factor best characterized for its neuronal functions but
which is also implicated in leukemia (49). Cross-species comparisons can also be usefully
combined with genetic interactions as illustrated by the co-mutation of Gata1 and Runx1.
Similar inferences could be made for whole chromosome gains and losses in human tumors
where the context of other mutations within the same tumor is known.
We find hundreds of significant associations between CISs and deficiency for different CDK
inhibitors. These associations may serve as an additional tool to direct large-scale mutation
detection studies of human tumors, particularly those deficient for these CDK inhibitors.
Although it is unlikely that we have identified all mutations from our tumors, approximately
1/3 of our insertions occur within CISs suggesting the presence of at least 6-7 driver
mutations per tumor. Stratton et al. (1) estimate that to define a single cancer genome in its
entirety will require more than 100,000,000,000 base pairs of DNA sequence in order to
provide adequate coverage of tumor DNA and somatic controls. As such, until every
patient's tumor genome can be sequenced in full, clinical approaches to mutation detection
can initially be better directed toward panning for frequent events. On the basis of these
results, a subset of the genome can then be screened for rare mutations, which are most
likely to occur within that context.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. MuLV insertion density over the genome
(A) Flow chart of the experimental setup (B) Insertions from all tumor panels were
combined to calculate the insertion density over the genome using a 30 kb kernel (21). The
cut-off (p-value 0.05) for significant insertion density is indicated by the red line. CISs (p-
value < 0.05) are indicated (green lines).
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Figure 2. Selection for mutation of prominent cancer genes in different genotypes
Using Fisher's exact test we examined whether each CIS is significantly more mutated in
each genotype versus every other genotype. P-values for each test are represented as a heat
map (significance is indicated by the color bar). Green squares indicate that a gene is
mutated more frequently in the genotype indicated on the vertical axis versus the genotype
on the horizontal axis. Red squares indicate a gene is more mutated in the genotype on the
horizontal axis verses the genotype on the vertical axis. CIS rank and CIS name are
indicated above each heat map (A) Heat maps for Myc/Pvt1 and Mycn (B) Heat maps for
Ccnd3 and Ccnd1 (C) Heat maps for mmu-mir-106-363 and mmu-mir-17-92.
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Figure 3. Identification of pairs of collaborative cancer genes
Co-occurrence or mutually exclusivity of CISs in multiple independent genotypes. The
interaction between CISs is represented as heat map, green squares in the two top rows
indicate if both CISs are co-mutated significantly more frequently than expected by chance.
Red squares in the lower two rows indicates both CISs are co-mutated less frequently than
expected by chance. In the first and third row of each combination the first CIS (e.g. Myb/
Ahi1) is assumed to be the predisposing, more clonal event and the second CIS (Rras2) to be
the subsequent, subclonal event. In the second and fourth row the reverse assumption is
tested. The left panel represents the p-value for the interaction for the pooled dataset, the
right panel for the individual genotypes. P-values for the interactions in the pooled dataset
are represented between the panels. (A) Myb/Ahi1 and Rras2 mutations co-occur (top)
whereas Myc/Pvt1 CIS1 and Mycn are mutually exclusive in different genotypes (bottom).
(B) CIS combinations in mice lacking both alleles of p19Arf (p19Arf−/− and p16−/− p19Arf−/−)
or (C) in p16−/− p19Arf−/− and p53−/− mice. (D) Mutual exclusivity of Rras2 and Map3k8
and mmu-mir-106a-363 and Fli1/Ets1 in the pooled dataset is not detected in the individual
tumor panels.
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Table 1
Gender-specific CISs
CISs significantly (p-value < 0.05) more mutated in females compared to males (and vice versa) are listed
(kernel width 30 kb).
Female-specific CISs (CIS rank-CIS) Inserts in males Inserts in females p-value
2 - Myc/Pvt1 CIS1 135 190 0.00075852
20 - Ccr7 11 29 0.0027343
257 - Trim25/Dgke 0 7 0.0073774
262 - Irf4 0 6 0.014878
162 - Gsdmc1 1 8 0.018412
367 - Myc/Pvt1 CIS5 0 5 0.030004
497 - BC038822 0 5 0.030004
515 - Slc43a2 0 5 0.030004
538 - BC067047/Trp53rk/Arfgef2 0 5 0.030004
554 - Tnfaip3 0 5 0.030004
584 - Pde4b 0 5 0.030004
588 - D230014K01Rik 0 5 0.030004
591 - Pkig 0 5 0.030004
209 - Ubac2 1 7 0.033414
4 - Ccnd3 CIS1 85 109 0.038146
Male-specific CISs Inserts in males Inserts in females p-value
52 - Ccnd2 CIS1 15 2 0.0013005
240 - Glb1/Crtap 7 0 0.0082522
366 - Ggta1/Dab2ip 6 0 0.016378
371 - AA536749/Olfr223 6 0 0.016378
375 - Arhgef3 CIS2 6 0 0.016378
382 - Brsk1(1500019G21Rik) 6 0 0.016378
410 - Nt5c2 6 0 0.016378
421 - B3gntl1 6 0 0.016378
58 - Thada/Zfp36l2 12 3 0.01892
227 - Cstad CIS2 8 1 0.020662
31 - Lck 19 8 0.028654
309 - Tcfap4 5 0 0.032504
424 - Abcb9 5 0 0.032504
474 - AB041803(MNCb-1768) CIS3 5 0 0.032504
483 - Psap/Cdh23/4632428N05Rik 5 0 0.032504
494 - Clec16a 5 0 0.032504
549 - Fub 5 0 0.032504
567 - Ngly1 5 0 0.032504
150 - Hrbl/Irs3 9 2 0.034658
188 - Cep97/Rpl24 7 1 0.036914
284 - Rhbdf2 7 1 0.036914
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Female-specific CISs (CIS rank-CIS) Inserts in males Inserts in females p-value
42 - Tmem189/Ptpn1/A530013C23Rik CIS2 12 4 0.041088
73 - Gfi1/Evi5 CIS1 10 3 0.04895
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Table 2
CISs associated with tumor latency
CISs significantly (p-value < 0.05) more frequently mutated in ‘short-latency’ mice compared to ‘long-
latency’ mice (and vice versa) are listed (kernel width 30 kb).








1 - Gfi1/Evi5 CIS2 0.0001 0.0001 45.19
12 - Mycn 0.0005 0.0049 40.28
158 - Tbxa2r 0.0041 0.0148 20.44
2 - Myc/Pvt1 CIS1 0.0051 0.0001 43.86
56 - Tcf7/Vdac1 0.0069 0.0333 29.58
292 - Plac8 0.0082 0.2457 31.48
154 - Btg2 0.0113 0.0604 23.88
39 - Rasgrp1 0.0143 0.0179 35.44
438 - Parvg 0.0162 0.0604 19.55
69 - Irf2bp2/Pard3 0.0187 0.1649 36.20
32 - Flt3 0.0233 0.0097 33.31
80 - Cd27/Vamp1/Tapbpl 0.0303 0.8072 44.90
485 - Gse1 0.0323 0.0299 13.79
486 - Cryba4 0.0323 0.1218 22.02
561 - Plekha6 0.0323 0.1218 23.60
344 - Tubb2a/Tubb2b 0.0323 0.2457 28.58
519 - Scml4 0.0323 0.2457 29.60
549 - Fyb 0.0323 0.4957 29.38
420 - 2610207I05Rik 0.0323 1.0000 31.92
195 - Hipk1 0.0366 0.1218 26.72
183 - Akna 0.1489 0.0148 31.41
40 - Rorc 0.4235 0.0183 39.29
24 - Pim2 0.1401 0.0266 36.91
233 - Dhx40 0.1489 0.0299 30.73
134 - Recql5 0.6312 0.0299 38.78
115 - Exoc2 0.1175 0.0333 32.91








11 - Notch1 0.0020 0.0037 55.95
209 - Ubac2 0.0037 0.0646 74.64
226 - Fli1 0.0037 0.0646 75.09
99 - Ints1/Mafk 0.0055 0.3189 61.61
22 - Zfp438 0.0075 0.0023 67.36
15 - Pik3r5 0.0080 0.0390 57.55
23 - Lfng 0.0090 0.0892 62.66
10 - Myc/Pvt1 CIS2 0.0109 0.0006 58.67
5 - Rras2 CIS1 0.0137 0.0175 55.24
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3 - Rasgrp1 CIS2 0.0145 0.0031 54.52
14 - Ikzf1 0.0145 0.1839 57.32
300 - Ncln 0.0150 0.2542 71.02
430 - Usp7 0.0150 0.2542 71.09
55 - Myc/Pvt1 0.0165 0.0083 69.62
220 - Ralgps2 0.0186 0.1133 73.81
142 - Exoc6 0.0186 0.0653 76.21
26 - mmu-mir-17-92a-1/Gpc5 0.0195 0.1401 59.56
97 - Rcsd1/Creg1 0.0311 0.0653 69.26
198 - 4921513I03Rik 0.0337 0.0653 73.33
238 - Tmie/Als2cl/Tdgf1 0.0337 0.2542 70.93
50 - Bcl2l1 0.0362 0.0653 61.14
17 - Map3k8 0.0437 0.0168 60.77
21 - Smg6/Hic1/Ovca2/mmu-mir-132/212 CIS1 0.4168 0.0040 57.63
8 - Myc/Pvt1 CIS4 0.0525 0.0066 55.61
290 - 2410014A08Rik 0.0603 0.0326 73.83
421 - B3gntl1 0.1063 0.0326 86.47
184 - Klf3 0.1665 0.0326 65.20
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Table 3
Significant enrichment of retroviral insertions in the vicinity of mouse orthologs of human
SNPs associated with familial CLL
Each SNP is mapped to the mouse genome and windows of 10 kb – 300 kb surrounding it examined for
retroviral inserts. All window sizes from 20 – 220 kb are significantly enriched with insertions.
Window size (kb) Inserts in region Inserts expected Fold enrichment p-value
10 12 6.57 1.83 0.108
20 27 11.51 2.35 0.028
30 37 16.55 2.24 0.026
40 47 21.45 2.19 0.027
50 61 25.97 2.35 0.018
60 74 30.47 2.43 0.015
70 92 35.20 2.61 0.016
80 94 39.97 2.35 0.019
90 98 44.58 2.20 0.022
100 105 49.23 2.13 0.024
110 116 53.85 2.15 0.023
120 119 58.30 2.04 0.025
130 129 62.86 2.05 0.025
140 131 67.50 1.94 0.027
150 131 72.24 1.81 0.034
160 133 77.03 1.73 0.04
170 136 81.63 1.67 0.047
180 144 86.18 1.67 0.048
190 155 91.21 1.70 0.046
200 165 96.26 1.71 0.046
210 174 101.04 1.72 0.045
220 177 105.80 1.67 0.049
230 178 110.41 1.61 0.052
240 186 115.36 1.61 0.054
250 189 119.98 1.58 0.061
260 195 124.91 1.56 0.061
270 202 130.01 1.55 0.064
280 212 134.81 1.57 0.062
290 217 139.70 1.55 0.067
300 225 144.07 1.56 0.066
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